Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA, tr
Target Price
The average target price of STOK is 36 and suggests 25% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell